研究单位：[1]department of general surgery, Fudan University[2]The Fourth Hospital of Hebei Medical University and Hebei Tumor Hospital Shijiazhuang, Hebei, China, 050011河北医科大学第四医院[3]Henan Cancer Hospital Zhengzhou, Henan, China, 450008[4]Xiangya Hospital of Central South University Changsha, Hunan, China, 410008[5]Affiliated Hospital Of Jiangnan University Wuxi, Jiangsu, China, 214122[6]Qilu Hospital of Shandong University (QLH) Jinan, Shandong, China, 250012[7]The Affiliated Hospital of Qingdao University Qingdao, Shandong, China, 266071[8]Changhai Hospital Shanghai, Shanghai, China, 200433[9]Ruijin Hospital Affiliated to The Shanghai Jiao Tong University Medical School Shanghai, Shanghai, China, 201801[10]the Second Affiliated Hospital of Medical College of Zhejiang University Hangzhou, Zhejiang, China, 310000[11]Zhejiang Provincial People's Hospital Hangzhou, Zhejiang, China, 310014[12]Sir Run Run Shaw Hospital Hangzhou, Zhejiang, China, 310016[13]The First Hospital of Putian City Putian, Fujian, China, 351100
This is a prospective, multi-center, randomized study evaluating the efficacy and safety of fruquintinib combined with chemotherapy vs bevacizumab combined with chemotherapy as second-line treatment in patients with metastatic colorectal cancer. Patients will receive fruquintinib+ FOLFIRI or bevacizumab+FOLFIRI as the second-line treatment. After receiving 4-6 months of second-line treatment, patients who achieve disease control will receive fruquintinib + capecitabine or bevacizumab+ capecitabine as maintenance treatment. All patients will be treated until progressive disease, death from any cause, unacceptable toxicity or informed consent withdrawal.
